Toward Clinical Trial Abundance

Bridging the Gap
from Biotech to Clinic.

Infinita helps biotechs navigate emerging pathways to early clinical access.
Emerging clinical access pathways are creating new routes from breakthrough science to patient care.
‍
Infinita helps treatment developers navigate those pathways responsibly.
‍
Discuss Your Treatment
Every treatment follows a different path.
Start with a conversation about yours.
01 Problem

Promising Therapies
Get Stuck.

Therapies can demonstrate early safety, yet remain years away from the patients who could benefit.
Many promising therapies fail for commercial—not scientific—reasons.



10+ Years

Conventional clinical development can take a decade or more, delaying patient access long after early safety has been demonstrated.



$1B+ Capital Required

Completing conventional clinical development can require more than $1 billion, causing many promising programs to stall before reaching patients.
Toward Clinical Trial Abundance.
02 Pathways

Emerging Pathways.

A growing network of jurisdictions expanding responsible clinical access.
These pathways differ in their legal frameworks, eligibility requirements, and oversight models, but they share the objective of enabling clinical access while continuing to generate evidence.

Infinita helps treatment developers understand these emerging options and identify the pathway best suited to their therapy.

Montana

New Hampshire

Prospera

Pathway Overview.

Montana established one of the first state-level frameworks allowing eligible patients to access certain experimental treatments following early safety evidence and independent expert review.

Technical Profile.

LOCATION:
Montana, US.
STATUS:
Live.
FRAMEWORK:
SB535.
ACCESS:
Early Clinical Access.
APPLICABILITY:
Pre- and post-Phase 1 therapies.